Transitional Cell Carcinoma Clinical Trial
Official title:
BCG + MMC: Adding Mitomycin C to BCG as Adjuvant Intravesical Therapy for High-risk, Non-muscle-invasive Bladder Cancer: a Randomised Phase 3 Trial
Instillation of Bacillus of Calmette-Guerin (BCG) into the urinary bladder (intravesical administration) improves rates of disease recurrence and progression after transurethral resection (TUR) of high risk, non-muscle-invasive bladder cancer (NMIBC), but over 30% of people still develop recurrent transitional cell carcinoma (TCC) despite optimal therapy with adjuvant intravesical BCG. Our meta-analysis, including a recent randomised phase 2 trial, suggests that outcomes might be improved further by using an adjuvant intravesical regimen that includes both Mitomycin (MM) and BCG. These promising findings require corroboration in a definitive, large scale, randomised phase 3 trial using standard techniques for intravesical administration.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT03296306 -
Four Cycles Versus Six Cycles of Cisplatin-based Chemotherapy in Metastatic Urothelial Carcinoma
|
Phase 3 | |
| Completed |
NCT00880334 -
Randomized Study of Docetaxel +/- Vandetanib in Metastatic TCC
|
Phase 2 | |
| Completed |
NCT00216801 -
Relationship of Ochratoxin A to Upper Urologic Cancers
|
N/A | |
| Withdrawn |
NCT04179110 -
Study of Pembrolizumab and Ramucirumab in Pts With Progressive TCC After Treatment With an Immune Checkpoint Inhibitor
|
Phase 2 | |
| Completed |
NCT00070070 -
Vaccine Therapy in Treating Patients With Transitional Cell Carcinomas
|
Phase 1 | |
| Completed |
NCT00154687 -
Weekly TP-HDFL in the Treatment of Advanced TCC
|
Phase 2 | |
| Completed |
NCT03256877 -
Detecting Transitional Cell Carcinoma From Haematuria
|
||
| Withdrawn |
NCT04006691 -
Efficacy and Safety of UGN-101 in Recurrent Patients
|
Phase 3 | |
| Terminated |
NCT05052372 -
Biomarker Research Study for Patients With FGFR-Mutant Bladder Cancer Receiving Erdafitinib
|
||
| Completed |
NCT00714025 -
A Single Arm, Multicenter, Phase II Trial of RAD001 as Monotherapy in the Palliative Treatment of Patients With TCC After Failure of Chemotherapy
|
Phase 2 | |
| Terminated |
NCT01310803 -
Multi-center Study to Evaluate the Efficacy and Safety of Maintenance Therapy With Valrubicin Versus no Maintenance, in Subjects Treated With Valrubicin Induction for Carcinoma in Situ (CIS) of the Bladder
|
Phase 3 | |
| Completed |
NCT00623831 -
A Phase 1 Study of Mixed Bacteria Vaccine (MBV) in Patients With Tumors Expressing NY-ESO-1 Antigen
|
Phase 1 | |
| Completed |
NCT00173862 -
Gemcitabine and Ifosfamide As a Second-Line Systemic Chemotherapy for Cisplatin -Failed Advanced TCC
|
Phase 2 | |
| Recruiting |
NCT03896958 -
The PIONEER Initiative: Precision Insights On N-of-1 Ex Vivo Effectiveness Research Based on Individual Tumor Ownership (Precision Oncology)
|
||
| Terminated |
NCT01438112 -
Efficacy Study of Recombinant Adenovirus for Non Muscle Invasive Bladder Cancer
|
Phase 2/Phase 3 | |
| Completed |
NCT00683059 -
Single Agent Abraxane as Second Line Therapy in Bladder Cancer
|
Phase 2 | |
| Recruiting |
NCT04811846 -
CTC Quantification During TURBT and PKVBT of Transitional Cell Carcinoma in Purging Fluid and Blood
|
N/A | |
| Not yet recruiting |
NCT04878250 -
Preoperative Bintrafusp Alfa in Operable Urothelial Carcinoma of the Bladder
|
Phase 2 | |
| Completed |
NCT00633789 -
Phase II Study of Brivanib (BMS-582664) to Treat Multiple Tumor Types
|
Phase 2 | |
| Completed |
NCT00612326 -
Feasibility Evaluation of Magnetic Resonance Imaging and Positron Emission Tomography for Bladder Cancer Diagnosis and Staging
|
N/A |